Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Joan T. Garrett, Anindita Chakrabarty, Carlos L Arteaga

Research output: Contribution to journalComment/debate

Abstract

This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

Original languageEnglish (US)
Pages (from-to)32400
Number of pages1
JournalOncotarget
Volume9
Issue number64
DOIs
StatePublished - Aug 17 2018
Externally publishedYes

Fingerprint

Proxy
Phosphatidylinositol 3-Kinases
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Correction : Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409. / Garrett, Joan T.; Chakrabarty, Anindita; Arteaga, Carlos L.

In: Oncotarget, Vol. 9, No. 64, 17.08.2018, p. 32400.

Research output: Contribution to journalComment/debate

@article{0bfb2092e4324f348381704874930af4,
title = "Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409",
abstract = "This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.",
author = "Garrett, {Joan T.} and Anindita Chakrabarty and Arteaga, {Carlos L}",
year = "2018",
month = "8",
day = "17",
doi = "10.18632/oncotarget.26017",
language = "English (US)",
volume = "9",
pages = "32400",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "64",

}

TY - JOUR

T1 - Correction

T2 - Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

AU - Garrett, Joan T.

AU - Chakrabarty, Anindita

AU - Arteaga, Carlos L

PY - 2018/8/17

Y1 - 2018/8/17

N2 - This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

AB - This article has been corrected: During production, the text of the subsections 'INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS' and 'CLINICAL IMPLICATIONS' was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

UR - http://www.scopus.com/inward/record.url?scp=85051769625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051769625&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26017

DO - 10.18632/oncotarget.26017

M3 - Comment/debate

C2 - 30190795

AN - SCOPUS:85051769625

VL - 9

SP - 32400

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 64

ER -